mumps vaccine
/ Sinovac
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 17, 2024
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
(clinicaltrials.gov)
- P4 | N=400 | Active, not recruiting | Sponsor: Sinovac Biotech Co., Ltd
New P4 trial • Infectious Disease • Influenza • Mumps • Respiratory Diseases
September 21, 2023
Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial.
(PubMed, PLoS One)
- "And most AEFI cases were common adverse reactions (66.67%, 38/57). In total, the live attenuated mumps vaccine evaluated in this trial has a favorable safety profile and can be used for large-scale inoculation."
Journal • P4 data • Infectious Disease • Mumps • Pain
December 06, 2021
Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old
(clinicaltrials.gov)
- P=N/A; N=10000; Completed; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Clinical • New trial • Infectious Disease
October 01, 2021
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
(clinicaltrials.gov)
- P3; N=1140; Completed; Sponsor: Sinovac Research and Development Co., Ltd.
Clinical • New P3 trial • Infectious Disease
August 18, 2021
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
(clinicaltrials.gov)
- P4; N=920; Completed; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.; Recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Apr 2021; Trial primary completion date: Jun 2020 ➔ Nov 2020
Clinical • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease
April 28, 2020
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
(clinicaltrials.gov)
- P4; N=920; Recruiting; Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Clinical • New P4 trial • Gene Therapies • Genetic Disorders • Infectious Disease
1 to 6
Of
6
Go to page
1